A carregar...

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel 175 mg m(-2) intravenously over 3 h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smit, E. F., Fokkema, E., Biesma, B., Groen, H. J., Snoek, W., Postmus, P. E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1998
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2151229/
https://ncbi.nlm.nih.gov/pubmed/9461009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!